KAILUA KONA, Hawaii, Mar 02, 2006 (BUSINESS WIRE) -- Cyanotech Corporation (CYAN) , a world leader in producing high-value nutrition and health products from microalgae, has completed a preliminary study of the effects of BioAstin Natural Astaxanthin in humans in reducing systemic inflammation as measured by levels of C-Reactive Protein (CRP) in blood serum.
The double-blind study by an independent research group of 15 subjects taking BioAstin and eight subjects taking Placebo found that subjects who took BioAstin for 56 days showed an average decrease in their measured CRP levels of over 20%. Subjects who took Placebo showed no such decrease. Analysis of the data showed that there was a statistically significant difference between the two treatment conditions, suggesting that BioAstin may significantly reduce CRP scores.
"While highly encouraging, this finding was based on a small sample size and, ideally, should be replicated in a larger study," said Dr. Gerald R. Cysewski, Chairman, President and CEO of Cyanotech. "Considering recent literature on the importance of CRP as an indicator of cardiac health, the finding of such a substantial average reduction in CRP after a regimen of BioAstin is a promising result that deserves further attention."
C-Reactive Protein (CRP) is one of the acute phase proteins that increase during systemic inflammation. Testing CRP levels in the blood may be a new way to assess cardiovascular disease risk, according to the American Heart Association ( www.americanheart.org).
Other research suggests that systemic or silent inflammation may be implicated in many life threatening diseases, such as cancer, heart disease, stroke, diabetes and Alzheimer's, among others.
"This study adds to the body of research being developed that supports the anti-inflammatory properties of BioAstin Natural Astaxanthin," noted Dr. Cysewski. "Previous studies have shown the benefit of using BioAstin for varied inflammation-related conditions, including rheumatoid arthritis, carpal tunnel syndrome, joint soreness and sunburn, among others."
Information about this research is available at www.cyanotech.com.
Cyanotech Corporation, a world leader in microalgae technology, produces BioAstin(R) Natural Astaxanthin and Hawaiian Spirulina Pacifica(R) -- all natural, functional nutrients that enhance human health and nutrition, providing significant antioxidant, anti-inflammatory and immune response benefits. NatuRose(R) Natural Astaxanthin is a natural pigment source that also promotes animal health and nutrition, primarily in aquaculture. Phycobiliproteins are fluorescent pigments used in medical diagnostic testing and research. Cyanotech produces these products from microalgae grown at its 90-acre facility in Hawaii using patented and proprietary technology. Cyanotech products are distributed to nutritional supplement, nutraceutical, cosmeceutical, and animal feed makers and marketers in more than 40 countries worldwide. Cyanotech was the first microalgae company in the world to obtain ISO 9001:2000 certification. Corporate data and product information are available at www.cyanotech.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Except for statements of historical fact, the statements in this news release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, forecasts of sales in future periods, changes in sales levels to Cyanotech's largest customers, weather patterns, production problems caused by contamination, risks associated with the acceptance of new products, competition, foreign exchange fluctuations, government regulation and other factors more fully detailed in the Company's recent Form 10-Q and annual form 10-K filings with the Securities and Exchange Commission.